Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.24 USD
+0.13 (0.27%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $48.26 +0.02 (0.04%) 7:38 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.24 USD
+0.13 (0.27%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $48.26 +0.02 (0.04%) 7:38 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
by Zacks Equity Research
Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.
Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update
by Zacks Equity Research
Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 8.74% and 1.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $70.35, moving -1.11% from the previous trading session.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
by Zacks Equity Research
Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $70.62 in the latest trading session, marking a -0.21% move from the prior day.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $68.48, moving -1.75% from the previous trading session.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $70.24 in the latest trading session, marking a -1.69% move from the prior day.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
by Zacks Equity Research
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
Is Exelixis' (EXEL) Growth Story Likely to Continue?
by Zacks Equity Research
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Should Investors Buy Bristol Myers Squibb Stock?
by Shaun Pruitt
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.